TPH1 and Cowden syndrome 1: The last drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of refractory CS was telotristat ethyl, an oral inhibitor of TPH, which represents the rate-limiting step in serotonin biosynthesis [36].